Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 177
2021 352
2022 352
2023 317
2024 206
2025 156

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,408 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for covid ds
Search for Covin DS instead (1 results)
Targeting the SARS-CoV-2 reservoir in long COVID.
Proal AD, Aleman S, Bomsel M, Brodin P, Buggert M, Cherry S, Chertow DS, Davies HE, Dupont CL, Deeks SG, Ely EW, Fasano A, Freire M, Geng LN, Griffin DE, Henrich TJ, Hewitt SM, Iwasaki A, Krumholz HM, Locci M, Marconi VC, Mehandru S, Muller-Trutwin M, Painter MM, Pretorius E, Price DA, Putrino D, Qian Y, Roan NR, Salmon D, Tan GS, VanElzakker MB, Wherry EJ, Van Weyenbergh J, Yonker LM, Peluso MJ. Proal AD, et al. Lancet Infect Dis. 2025 May;25(5):e294-e306. doi: 10.1016/S1473-3099(24)00769-2. Epub 2025 Feb 10. Lancet Infect Dis. 2025. PMID: 39947217 Review.
There are no approved treatments for post-COVID-19 condition (also known as long COVID), a debilitating disease state following SARS-CoV-2 infection that is estimated to affect tens of millions of people. A growing body of evidence shows …
There are no approved treatments for post-COVID-19 condition (also known as long COVID), a debilitating disease state f …
Symptoms and risk factors for long COVID in non-hospitalized adults.
Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, Taverner T, Chandan JS, Brown K, Simms-Williams N, Shah AD, Singh M, Kidy F, Okoth K, Hotham R, Bashir N, Cockburn N, Lee SI, Turner GM, Gkoutos GV, Aiyegbusi OL, McMullan C, Denniston AK, Sapey E, Lord JM, Wraith DC, Leggett E, Iles C, Marshall T, Price MJ, Marwaha S, Davies EH, Jackson LJ, Matthews KL, Camaradou J, Calvert M, Haroon S. Subramanian A, et al. Nat Med. 2022 Aug;28(8):1706-1714. doi: 10.1038/s41591-022-01909-w. Epub 2022 Jul 25. Nat Med. 2022. PMID: 35879616 Free PMC article.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with a range of persistent symptoms impacting everyday functioning, known as post-COVID-19 condition or long COVID. ...We selected 486,149 adults with co …
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with a range of persistent symptom …
Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome.
Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, Mostyka M, Baxter-Stoltzfus A, Borczuk AC, Loda M, Cody MJ, Manne BK, Portier I, Harris ES, Petrey AC, Beswick EJ, Caulin AF, Iovino A, Abegglen LM, Weyrich AS, Rondina MT, Egeblad M, Schiffman JD, Yost CC. Middleton EA, et al. Blood. 2020 Sep 3;136(10):1169-1179. doi: 10.1182/blood.2020007008. Blood. 2020. PMID: 32597954 Free PMC article.
We studied the connection between NETs and COVID-19 severity and progression. We conducted a prospective cohort study of COVID-19 patients (n = 33) and age- and sex-matched controls (n = 17). ...Finally, COVID-19 neutrophils ex vivo displ …
We studied the connection between NETs and COVID-19 severity and progression. We conducted a prospective cohort study of CO …
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, An Y, Cheng Y, Li S, Liu M, Yang M, Li Y, Cheng H, Yuan Y, Zhang W, Ke C, Wong G, Qi J, Qin C, Yan J, Gao GF. Dai L, et al. Cell. 2020 Aug 6;182(3):722-733.e11. doi: 10.1016/j.cell.2020.06.035. Epub 2020 Jun 28. Cell. 2020. PMID: 32645327 Free PMC article.
Vaccines are urgently needed to control the ongoing pandemic COVID-19 and previously emerging MERS/SARS caused by coronavirus (CoV) infections. The CoV spike receptor-binding domain (RBD) is an attractive vaccine target but is undermined by limited immunogenicity. . …
Vaccines are urgently needed to control the ongoing pandemic COVID-19 and previously emerging MERS/SARS caused by coronavirus …
CHA(2)DS(2)-VASc Score as Predictor of New-Onset Atrial Fibrillation and Mortality in Critical COVID-19 Patients.
Ioannidis PS, Sileli M, Kerezidou E, Kamaterou M, Iasonidou C, Kapravelos N. Ioannidis PS, et al. J Intensive Care Med. 2024 Nov;39(11):1155-1163. doi: 10.1177/08850666241272068. Epub 2024 Aug 7. J Intensive Care Med. 2024. PMID: 39109625 Review.
Moreover, it predicted adverse outcomes in other clinical conditions, including SARS-CoV-2 infection. We aimed to evaluate the association of CHA(2)DS(2)-VASc with NOAF, ICU length of stay (LOS) and mortality in critically ill COVID-19 pa …
Moreover, it predicted adverse outcomes in other clinical conditions, including SARS-CoV-2 infection. We aimed to evalu …
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade.
Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A; D3CODE Team; Lee J, Lee JH, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. Grippin AJ, et al. Nature. 2025 Nov;647(8089):488-497. doi: 10.1038/s41586-025-09655-y. Epub 2025 Oct 22. Nature. 2025. PMID: 41125896 Free PMC article.
Here we show that mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to ICIs. In preclinical models, SARS-CoV-2 mRNA vaccines led to a substantial increase in type I interferon, enabling innate immune cells to prime CD8(+) T cells …
Here we show that mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to ICIs. In preclinical models, SARS …
Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis.
Iddir M, Brito A, Dingeo G, Fernandez Del Campo SS, Samouda H, La Frano MR, Bohn T. Iddir M, et al. Nutrients. 2020 May 27;12(6):1562. doi: 10.3390/nu12061562. Nutrients. 2020. PMID: 32471251 Free PMC article. Review.
The coronavirus-disease 2019 (COVID-19) was announced as a global pandemic by the World Health Organization. Challenges arise concerning how to optimally support the immune system in the general population, especially under self-confinement. ...In this review, we hi …
The coronavirus-disease 2019 (COVID-19) was announced as a global pandemic by the World Health Organization. Challenges arise …
Therapeutic advances in COVID-19.
Murakami N, Hayden R, Hills T, Al-Samkari H, Casey J, Del Sorbo L, Lawler PR, Sise ME, Leaf DE. Murakami N, et al. Nat Rev Nephrol. 2023 Jan;19(1):38-52. doi: 10.1038/s41581-022-00642-4. Epub 2022 Oct 17. Nat Rev Nephrol. 2023. PMID: 36253508 Free PMC article. Review.
These treatments are spread across seven main therapeutic categories: anti-inflammatory agents, antivirals, antithrombotics, therapies for acute hypoxaemic respiratory failure, anti-SARS-CoV-2 (neutralizing) antibody therapies, modulators of the renin-angiote …
These treatments are spread across seven main therapeutic categories: anti-inflammatory agents, antivirals, antithrombotics, therapies for a …
Coronavirus envelope protein activates TMED10-mediated unconventional secretion of inflammatory factors.
Liu L, Zhang L, Hao X, Wang Y, Zhang X, Ge L, Wang P, Tian B, Zhang M. Liu L, et al. Nat Commun. 2024 Oct 8;15(1):8708. doi: 10.1038/s41467-024-52818-0. Nat Commun. 2024. PMID: 39379362 Free PMC article.
Here we identify the envelope (E) protein in severe coronaviruses (SARS-CoV-2, SARS, or MERS) as a potent inducer of interleukin-1 release, intensifying lung inflammation through the activation of TMED10-mediated unconventional protein secretion (UcPS). ...Th …
Here we identify the envelope (E) protein in severe coronaviruses (SARS-CoV-2, SARS, or MERS) as a potent inducer of in …
1,408 results